ALGS vs LLY
Valuation
Profitability
Growth
Financial Health
Dividends
AI Verdict
ALGS exhibits severe financial distress, reflected in a Piotroski F-Score of 0/9 and a lack of Altman Z-Score, indicating extreme bankruptcy risk. The company reports massive negative profitability metrics, including a -12,907.69% operating margin and -196.91% ROE, alongside a 73.1% YoY revenue decline. Despite a strong analyst consensus of 'strong_buy' and a high target price of $80.25, the stock trades at a premium valuation (Price/Sales of 21.31) with no earnings or cash flow generation. Insider sentiment is neutral, and technical trends are bearish, underscoring a lack of market confidence. The combination of deteriorating fundamentals and speculative valuation creates a high-risk profile.
LLY shows neutral fundamentals based on deterministic rules. Financial strength is weak (F-Score 3/9). Mixed signals with both opportunities and risks present.
Compare Another Pair
Related Comparisons
ALGS vs LLY: Head-to-Head Comparison
This page compares Aligos Therapeutics, Inc. (ALGS) and Eli Lilly and Company (LLY) across key fundamental metrics including valuation ratios, profitability margins, growth rates, financial health indicators, and dividend metrics. Each metric highlights the better-performing stock so you can quickly identify relative strengths and weaknesses.
Our AI engine independently analyzes each company's financials, competitive position, and market conditions to produce a verdict (Bullish, Neutral, or Bearish) along with key strengths and risks. Use this comparison alongside your own research to make informed investment decisions.